Thermo Fisher Scientific (TMO) Consolidated Net Income (2009 - 2026)

Thermo Fisher Scientific has disclosed Consolidated Net Income across 18 years of filings, most recently posting $1.7 billion for Q1 2026.

• Quarterly Consolidated Net Income rose 9.11% year-over-year to $1.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 billion (up 4.61% YoY) and the FY2025 annual result came in at $6.8 billion, up 5.97% from the prior year.
• Consolidated Net Income slipped to $1.7 billion in Q1 2026, from $2.0 billion in the prior quarter.
• Over five years, Consolidated Net Income peaked at $2.2 billion in Q2 2022 and troughed at $1.3 billion in Q1 2024.
• A 5-year average of $1.6 billion and a median of $1.6 billion in 2025 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2023 — Consolidated Net Income sank 41.18% — and 2024, when it grew 18.8%.
• Tracing TMO's Consolidated Net Income over 5 years: stood at $1.6 billion in 2022, then climbed by 0.19% to $1.6 billion in 2023, then climbed by 11.45% to $1.8 billion in 2024, then increased by 11.67% to $2.0 billion in 2025, then slipped by 16.8% to $1.7 billion in 2026.
• Business Quant data shows TMO's Consolidated Net Income at $1.7 billion in Q1 2026, $2.0 billion in Q4 2025, and $1.6 billion in Q3 2025.